Lyric Biosciences Inc.

Lyric Biosciences Inc. is a San Francisco-based biotech firm dedicated to developing innovative human immunoglobulin products, utilizing advanced bioreactor technology for efficient production processes. Founded in 2024, Lyric Biosciences Inc. operates from its headquarters in San Francisco, US, focusing on the development of human immunoglobulin therapies.

In December 2025, Lyric Biosciences Inc. raised USD 6. 6 million in seed funding led by new investor The Venture Collective, with participation from other new investors Black Diamond Ventures, Draper & Associates Inc, Lucas Venture Group, and Meiji Seika Pharma Co. , Ltd.

Returning investor SOSV and other unspecified investors also participated in the round. The founder's history is not publicly detailed. Lyric Bio, Inc. specializes in the development and manufacturing of human immunoglobulin (Ig) products, utilizing proprietary bioreactor technology that mimics biological tissue.

Their core innovation involves a novel laser-printed cellular substrate that supports ultra-high-density cell growth, enabling the continuous production of human Ig from a single donor. This advancement significantly reduces the reliance on traditional blood and plasma donations, where an average of 10 plasma donations are typically needed to produce one dose of intravenous immunoglobulin (IvIg). By providing a more stable and scalable supply of Ig therapies, Lyric Bio aims to address global shortages of critical therapeutics used in the treatment of over 100 diseases. The company targets various geographical markets including North America, Europe, and Asia, seeking to facilitate better access to life-saving therapies for healthcare providers and patients in these regions.

Lyric Bio generates revenue through direct partnerships and collaborations with pharmaceutical companies and healthcare providers that require human immunoglobulin therapies. The company structures transactions to ensure a consistent supply of its products, leveraging its innovative manufacturing processes to offer high-quality Ig products. Customers may enter into agreements based on volume purchase contracts, allowing for predictable pricing and enhanced supply chain stability. Their flagship products include various formulations of intravenous and subcutaneous immunoglobulin, specifically designed to meet the needs of healthcare systems and patients.

Pricing plans are tailored to the scale of production and the specific therapeutic requirements of clients, facilitating a robust revenue model centered around delivering critical therapeutics efficiently. The company plans to utilize the December 2025 funding to expand its biomanufacturing platform, initially focusing on improving IVIg production.